{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:39:24Z","timestamp":1781789964763,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company, Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12325-025-03294-5","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T12:33:48Z","timestamp":1753965228000},"page":"4950-4963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Safety and Efficacy of Pemafibrate to Treat Hyperlipidemia: Post-marketing Surveillance Over a 24-Month Observation Period in Japan"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3960-7883","authenticated-orcid":false,"given":"Mao","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shingaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Gunji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Makinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-1979","authenticated-orcid":false,"given":"Shun","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"3294_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11883-023-01153-8","volume":"25","author":"BN Wadstr\u00f6m","year":"2023","unstructured":"Wadstr\u00f6m BN, Wulff AB, Pedersen KM, Nordestgaard BG. Do triglyceride-rich lipoproteins equal low-density lipoproteins in risk of ASCVD? Curr Atheroscler Rep. 2023;25:795\u2013803.","journal-title":"Curr Atheroscler Rep"},{"key":"3294_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.5551\/jat.GL2022","volume":"31","author":"T Okamura","year":"2024","unstructured":"Okamura T, Tsukamoto K, Arai H, et al. Japan Atherosclerosis Society (JAS) Guidelines for prevention of atherosclerotic cardiovascular diseases 2022. J Atheroscler Thromb. 2024;31:641\u2013853.","journal-title":"J Atheroscler Thromb"},{"key":"3294_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","volume":"32","author":"MJ Chapman","year":"2011","unstructured":"Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345\u201361.","journal-title":"Eur Heart J"},{"key":"3294_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1475-2840-12-82","volume":"12","author":"JC Fruchart","year":"2013","unstructured":"Fruchart JC. Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists. Cardiovasc Diabetol. 2013;12:82.","journal-title":"Cardiovasc Diabetol"},{"key":"3294_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"JC Fruchart","year":"2017","unstructured":"Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16:124.","journal-title":"Cardiovasc Diabetol"},{"key":"3294_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12933-019-0864-7","volume":"18","author":"JC Fruchart","year":"2019","unstructured":"Fruchart JC, Santos RD, Aguilar-Salinas C, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol. 2019;18:71.","journal-title":"Cardiovasc Diabetol"},{"key":"3294_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.31662\/jmaj.2020-0104","volume":"4","author":"H Bando","year":"2021","unstructured":"Bando H, Taneda S, Manda N. Efficacy and safety of low-dose pemafibrate therapy for hypertriglyceridemia in patients with type\u00a02 diabetes. JMA J. 2021;4:135\u201340.","journal-title":"JMA J"},{"key":"3294_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"261","author":"H Arai","year":"2017","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144\u201352.","journal-title":"Atherosclerosis"},{"key":"3294_CR9","first-page":"453","volume":"51","author":"S Ishibashi","year":"2023","unstructured":"Ishibashi S, Yoshida T, Nakanishi M, et al. A long-term, prospective post-marketing surveillance of pemafibrate: interim report at 3\u00a0months. Jpn Pharmacol Ther. 2023;51:453\u20137.","journal-title":"Jpn Pharmacol Ther"},{"key":"3294_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","volume":"25","author":"H Arai","year":"2018","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25:521\u201338.","journal-title":"J Atheroscler Thromb"},{"key":"3294_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/ijms20030706","volume":"20","author":"K Yokote","year":"2019","unstructured":"Yokote K, Yamashita S, Arai H, et al. Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator (SPPARM\u03b1), in dyslipidemic patients with renal impairment. Int J Mol Sci. 2019;20:706.","journal-title":"Int J Mol Sci"},{"key":"3294_CR12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/dom.13686","volume":"21","author":"E Araki","year":"2019","unstructured":"Araki E, Yamashita S, Arai H, et al. Efficacy and safety of pemafibrate in people with type\u00a02 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study. Diabetes Obes Metab. 2019;21:1737\u201344.","journal-title":"Diabetes Obes Metab"},{"key":"3294_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase\u00a03 trial. J Clin Lipidol. 2018;12:173\u201384.","journal-title":"J Clin Lipidol"},{"key":"3294_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/jdi.12845","volume":"9","author":"I Matsuba","year":"2018","unstructured":"Matsuba I, Matsuba R, Ishibashi S, et al. Effects of a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. J Diabetes Investig. 2018;9:1323\u201332.","journal-title":"J Diabetes Investig"},{"key":"3294_CR15","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387:1923\u201334.","journal-title":"N Engl J Med"},{"key":"3294_CR16","unstructured":"Kowa Co. Ltd. Pharmaceutical risk management plan for Parmodia Tablets 0.1mg, Parmodia XR Tablets 0.2mg, Parmodia XR Tablets 0.4mg. 2018. https:\/\/medical.kowa.co.jp\/asset\/item\/72\/12-rmp_175.pdf. Accessed 12 Feb 2025."},{"key":"3294_CR17","unstructured":"Kowa Co. Ltd. Package insert\u2014Parmodia tablets 0.1mg. 2024. https:\/\/kowa-pharma.asia\/common\/pdf\/Parmodia_Tablet_0.1mg_Package_Insert.pdf. Accessed 12 Feb 2025."},{"key":"3294_CR18","first-page":"58","volume":"15","author":"PA Torres","year":"2015","unstructured":"Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015;15:58\u201369.","journal-title":"Ochsner J"},{"key":"3294_CR19","doi-asserted-by":"publisher","first-page":"3c","DOI":"10.1016\/j.amjcard.2006.11.016","volume":"99","author":"MH Davidson","year":"2007","unstructured":"Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99:3c\u201318c.","journal-title":"Am J Cardiol"},{"key":"3294_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","volume":"249","author":"S Ishibashi","year":"2016","unstructured":"Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase\u00a02 trial. Atherosclerosis. 2016;249:36\u201343.","journal-title":"Atherosclerosis"},{"key":"3294_CR21","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type\u00a02 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849\u201361.","journal-title":"Lancet"},{"key":"3294_CR22","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1515\/cclm-2012-0372","volume":"50","author":"G Lippi","year":"2012","unstructured":"Lippi G, Plebani M. Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here? Clin Chem Lab Med. 2012;50:2075\u201380.","journal-title":"Clin Chem Lab Med"},{"key":"3294_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1160\/TH05-01-0067","volume":"94","author":"A Undas","year":"2005","unstructured":"Undas A, Celinska-L\u00f6wenhoff M, Domagala TB, et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost. 2005;94:193\u20139.","journal-title":"Thromb Haemost"},{"key":"3294_CR24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2337\/dc17-1589","volume":"41","author":"E Araki","year":"2018","unstructured":"Araki E, Yamashita S, Arai H, et al. Effects of pemafibrate, a novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with type\u00a02 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase\u00a03 trial. Diabetes Care. 2018;41:538\u201346.","journal-title":"Diabetes Care"},{"key":"3294_CR25","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jacl.2018.06.010","volume":"12","author":"S Yamashita","year":"2018","unstructured":"Yamashita S, Arai H, Yokote K, Araki E, Suganami H, Ishibashi S. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. J Clin Lipidol. 2018;12:1267-79.e4.","journal-title":"J Clin Lipidol"},{"key":"3294_CR26","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.3390\/ijms20225537","volume":"20","author":"S Yamashita","year":"2019","unstructured":"Yamashita S, Arai H, Yokote K, et al. Efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1): pooled analysis of phase\u00a02 and 3 studies in dyslipidemic patients with or without statin combination. Int J Mol Sci. 2019;20:5537.","journal-title":"Int J Mol Sci"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03294-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03294-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03294-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:09:12Z","timestamp":1758899352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03294-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3294"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03294-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mao Watanabe, Michiko Nakanishi, Wataru Shingaki, Ryoji Gunji, Yuichi Makinose, and Takashi Kanno are employees of Kowa Company, Ltd. Shun Ishibashi has received personal fees from Kowa Company, Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This PMS study was conducted in compliance with the \u201cOrdinance of the Ministry of Health, Labour and Welfare (No. 171 of December 20, 2004) concerning standards for post-marketing surveillance and testing of pharmaceuticals\u201d (Ordinance on the Good Post-Marketing Study Practice) and other relevant laws and regulations in Japan. This PMS protocol was agreed to by the Japanese regulatory authority (Pharmaceuticals and Medical Devices Agency). Participating institutes were contracted by Kowa Company, Ltd. Ordinance on the Good Post-Marketing Study Practice does not specify ethical review committee deliberations or the need to obtain informed consent from patients. Therefore, deliberations by ethical review committees at participating institutes were conducted at the discretion of each site. Of all 612 participating institutes, 70 required ethical approval of the study protocol, which was granted by the relevant ethical review committee at each study site. Four of those 70 institutes also required written patient consent, which was successfully obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}